Progressive Improvement in Safety and Efficacy Vital for Steady Growth of Intravenous Immunoglobulin Market
Administration of intravenous immunoglobulin (IVIG) is an antibody-based therapy for a multitude of diseases. Intravenous immunoglobulin primarily contains IgG antibodies collected from several donors and is administered periodically according to the severity of the disease. The diversity of diseases that can be cured with intravenous immunoglobulin, aided by the frequent off-label use of IVIG, is a prime factor boosting the demand from the global intravenous immunoglobulin market.
According to Transparency Market Research (TMR), the global intravenous immunoglobulin market was valued at US$7.2 bn in 2015. Exhibiting a robust 8.5% CAGR, the market is expected to double in valuation between 2016 and 2024, with a valuation of US$14.9 bn expected for the intravenous immunoglobulin market by the end of 2024.
What are the key drivers for the intravenous immunoglobulin market?
The prime driver for the global intravenous immunoglobulin market is the rising incidence of autoimmune diseases, which are the key application of IVIG. Since donor immunoglobulins are a direct replacement for the patient’s own antibodies, intravenous immunoglobulin can be used to treat several autoimmune diseases.
The rising off-label use of intravenous immunoglobulin to treat primary and secondary immunodeficiency disorders as well as some neurological conditions is another leading driver for the global intravenous immunoglobulin market. Intravenous immunoglobulin has been shown to have a net positive effect (since it has some noteworthy side effects) in several conditions, which has ensured steady demand from the global IVIG market in the coming years.
The steady technological advancement in the intravenous immunoglobulin industry has also been a key driver for the market, as it has resulted in safer and more efficient production processes for IVIG. This has helped reduce the severity and frequency of the side effects of intravenous immunoglobulin, which has helped improve patient confidence. It has also made compliance with safety requirements significantly easier for IVIG producers. However, this has also led to the development of recombinant IVIG, which has the potential to replace conventionally procured IVIG in many applications.
Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/intravenous-immunoglobulin-market.htm
What are the key segments of the intravenous immunoglobulin market?
By end use, the global intravenous immunoglobulin market is segmented into hospitals, home care, and clinics. Of these, hospitals are likely to retain a dominant share in the global IVIG market in the coming years.
However, despite the steady dominance of the hospitals segment, the demand for intravenous immunoglobulin in home care is likely to exhibit rapid demand in the coming years. Since IVIG treatments are time-consuming but not particularly complicated, they can be readily administered in home care settings. The rising availability of home healthcare infrastructure due to the rising patient preference to receive healthcare in the familiar environs of their home is thus likely to remain a key driver for the intravenous immunoglobulin market in the coming years.
Geographically, North America is the leading contributor to the global intravenous immunoglobulin market. The relative ease of incorporating technological advances in the healthcare sector in developed countries such as the U.S. and Canada has boosted the North America IVIG market’s share. Though North America is likely to remain the key regional market for intravenous immunoglobulin, Asia Pacific is expected to exhibit rapid growth in the coming years due to the rising prevalence of autoimmune diseases in emerging countries in the region.